“I am pleased to share that we continue to make considerable progress across our focused markets. In FY26, we recorded our highest-ever yearly revenue of INR 28,163 Cr, reflecting the strength of our core businesses despite certain markets facing near-term challenges. Our One-India business surpassed the INR 12,500 Cr annual revenue milestone. Key therapies in Branded Prescription business delivered robust double-digitgrowth, Trade Generics business sustained the strong growth momentum and anchor brands of Consumer Health Business maintained leadership position. The US business posted an annual revenue of USD 780 Mn supported by demand in our differentiated portfolio and a steady base business. In One Africa, we recorded a healthy annual growth of 7% YoY in USD terms, driven by firm performance across key markets. Emerging Markets and Europe crossed the USD 400 Mn+ annualised revenue threshold on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front,” said Achin Gupta MD and Global CEO, Cipla.
